Therapeutic Viruses Move From Concept to Antimicrobial Strategy
Antimicrobial resistance is no longer confined to hospital antibiograms or isolated outbreak reports. It now cuts across human medicine, veterinary care, agriculture, and the environment, where repeated antimicrobial exposure selects for organisms that can survive once-reliable drugs. In this review, therapeutic viruses emerge as a serious translational idea rather than a laboratory curiosity, with bacteriophages, virophages, and mycoviruses positioned as possible complements to conventional antimicrobials.
The clinical appeal is straightforward. If bacteria, fungi, and other pathogens can evolve resistance to chemical agents, then biological antagonists that co-evolved with those organisms may offer a different route of control. Viral therapies do not replace stewardship, source control, or vaccination, but they expand the conceptual space for treating infections that no longer respond well to standard agents. For clinicians facing multidrug-resistant infections, the value lies in mechanism: these viruses act with specificity, target microbial physiology in distinct ways, and may be engineered or formulated to improve delivery against organisms that have outmaneuvered antibiotic classes.
One sentence captures the urgency: AMR is a One Health problem, not a single-discipline problem.
Why Resistance Keeps Expanding Across Human and Environmental Systems
The review frames AMR as the product of repeated selective pressure layered onto interconnected ecosystems. In human care, inappropriate prescribing and incomplete treatment courses help resistant strains survive. In veterinary medicine and agriculture, antimicrobial exposure can shape microbial populations in animals and food systems, while environmental contamination adds another reservoir for resistance genes and resistant organisms. Those pathways do not remain isolated; they circulate through communities, hospitals, farms, wastewater, and food chains, creating a persistent feedback loop.
Biologically, resistance develops through familiar routes: altered drug targets, enzymatic drug inactivation, reduced permeability, active efflux, and other adaptive mechanisms that blunt antimicrobial effect. Once those defenses become established, standard agents lose potency and the margin for empiric treatment narrows. That is especially consequential when infection severity demands immediate therapy and susceptibility results arrive late. The review uses that reality to justify looking beyond conventional antimicrobial classes and toward virus-based options that can sidestep some of the same resistance pathways.
Bacteriophages as Precision Tools Against Bacterial Infection
Among the virus-based approaches discussed, bacteriophages are the most developed. These viruses infect bacteria, replicate within them, and can ultimately lyse the host cell. Their therapeutic logic rests on species or strain specificity, which can be a strength and a constraint at the same time. Specificity may spare much of the native microbiota and reduce collateral disruption compared with broad-spectrum antibiotics, yet it also means the right phage must match the target organism closely.
That matching problem is not trivial at the bedside. A patient with a resistant bacterial infection may need rapid therapeutic selection, while the phage available in a formulation or library may not fit the exact strain. Manufacturing, purification, dosing, and stability then become as important as antimicrobial activity itself. The review places pharmaceutical formulation at the center of the discussion because a biologic therapy fails clinically if it cannot survive storage, reach the infection site, or maintain activity in a usable dose form.
A second clinical consideration is adaptation. Bacteria can evolve phage resistance, just as they evolve antibiotic resistance. Even so, phages bring a different evolutionary dynamic: they can be selected, combined, or reformulated, and their replication at the site of infection may amplify local antibacterial pressure. In principle, that makes them attractive for difficult-to-treat infections where standard options have narrowed to one or two agents with limited durability.
Virophages and Mycoviruses Extend the Concept Beyond Bacteria
The review also includes virophages and mycoviruses, extending the discussion beyond bacterial disease. Virophages are viruses that parasitize other viruses, while mycoviruses infect fungi. Their presence in this review matters because antimicrobial resistance is not limited to bacteria; fungal pathogens also create major treatment problems, especially when antifungal options are limited or poorly tolerated.
Mycoviruses are particularly interesting as a translational concept because fungal infections can become increasingly difficult to treat when resistance or drug intolerance reduces standard choices. The therapeutic logic is less familiar than phage therapy, but the same broad principle applies: use a virus that exploits the pathogen’s own biology to weaken or suppress it. This is not a simple copy-and-paste strategy from antibacterial therapy. Fungal cells differ substantially from bacteria in structure and physiology, so any viral approach must be tailored to the organism, the host, and the intended route of delivery.
Pharmaceutical Formulation Will Decide Whether These Therapies Reach Practice
Mechanism alone will not move therapeutic viruses into routine care. Pharmaceutical formulation determines whether the active agent remains viable long enough to matter, whether it can be delivered at the right concentration, and whether it can be administered in a way that is practical for real patients. Stability during storage, compatibility with excipients, protection from degradation, and preservation of infectivity all shape the feasibility of these products.
The review treats formulation as a translational bottleneck because virus-based antimicrobials are not standard small molecules. They behave more like biologic platforms, with greater sensitivity to manufacturing conditions and tighter dependencies on delivery context. A topical product, inhaled preparation, or systemic formulation each raises different barriers. For example, an agent intended for respiratory infection must survive the chemistry of aerosolization and reach infected tissue in an active state; an agent for wound infection must remain active in a complex inflammatory environment rich in enzymes, debris, and variable pH.
One practical implication follows directly: therapeutic viruses will succeed only if microbiology, pharmacy, and clinical deployment are developed together.
What Translational Progress Will Require Next
The review closes by positioning virus-based antimicrobials as part of a broader effort to address AMR before the available drug list becomes too short for safe empiric treatment. The next phase is unlikely to be driven by a single breakthrough. It will require better pathogen matching, standardized manufacturing, clearer formulation strategies, and clinical pathways that can integrate these agents into infection management without sacrificing safety or speed.
Equally important is the One Health frame. Resistance pressure does not begin and end with the prescription pad. It is shaped by stewardship in human health, antimicrobial use in animals, agricultural policy, and environmental contamination. Virus-based therapies may widen the antimicrobial toolbox, but they will not succeed in isolation from those system-level pressures.
The review does not provide clinical trial endpoints or comparative efficacy data. Its value lies elsewhere: it maps a biologically plausible, formulation-dependent, and clinically relevant path for bacteriophages, virophages, and mycoviruses at a time when conventional antimicrobial options continue to erode.